NF-kB Pathway

Venue: Boston

Location: Boston, Massachusetts, United States

Event Date/Time: Oct 27, 2004
Report as Spam


NF-kB and its signaling pathway are presently the focus of drug discovery and development programs for inflammatory diseases, cancer and autoimmune diseases. How are the successes of TNF-a modulators, proteasome inhibitors and kinase inhibitors giving rise to interest in pursuing other targets within this signal transduction pathway? What are the novel molecular targets for therapeutic intervention? And how are companies approaching the challenges associated with working in this area?

This innovative American Conference Institute event on Navigating the NF-kB Pathway for Drug Development will provide you with the latest information on the strategies that industry and academia are taking to exploit the NF-kB pathway in the pursuit of novel classes of therapies, and will feature a case study on the development of a currently marketed drug in this area. The superb faculty of notable academic leaders as well industry scientists with expertise in the NF-kB field will share their research, results and insights on:

Designing a successful development plan
New tactics for blocking activation of the TNF-a-NF-kB system
Identifying novel signaling molecules
Blocking NF-kB mediated transcription
Targeting the ubiquitin-proteasome system for cancer
RNAi for target identification and validation
Utilizing a systems biology approach to map the TNF-a-NF-kB signal transduction pathway